Strs Ohio lifted its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 51.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 146,100 shares of the medical instruments supplier’s stock after buying an additional 49,419 shares during the quarter. Strs Ohio owned about 0.39% of Harvard Bioscience worth $464,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Engineers Gate Manager LP bought a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $112,000. Marshall Wace LLP acquired a new position in shares of Harvard Bioscience in the third quarter valued at $123,000. Alambic Investment Management L.P. acquired a new position in shares of Harvard Bioscience in the third quarter valued at $138,000. Greenwood Capital Associates LLC acquired a new position in shares of Harvard Bioscience in the third quarter valued at $287,000. Finally, Citadel Advisors LLC acquired a new position in shares of Harvard Bioscience in the third quarter valued at $314,000. 74.34% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ HBIO opened at $3.55 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.83 and a quick ratio of 1.49. The firm has a market capitalization of $123.43 million, a P/E ratio of 71.00 and a beta of 1.38. Harvard Bioscience, Inc. has a one year low of $2.75 and a one year high of $6.70.
Separately, ValuEngine lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th.
WARNING: “Strs Ohio Purchases 49,419 Shares of Harvard Bioscience, Inc. (HBIO)” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2019/02/12/strs-ohio-purchases-49419-shares-of-harvard-bioscience-inc-hbio.html.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Featured Article: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.